A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial.
The company, named March Biosciences, will enter Phase 2 early next year with an autologous CAR-T cell therapy for relapsed and refractory CD5+ T cell lymphoma, it said Wednesday morning. CEO Sarah Hein told
Endpoints News
its total financing to date of $51 million won’t fully fund the upcoming
Phase 2,
which will take place at multiple sites in the US.
The candidate, MB-105, went through a
Phase 1
a